DCM
ARRY

Delpha Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Delpha Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-75
Closed -$1K – 1581
2017
Q4 		$1K Buy
+75
New +$853 ﹤0.01% 1626

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Delpha Capital Management's ARRY Position: Q1 2018 in Review

Delpha Capital Management sold out of Array Biopharma Inc (ARRY) in Q1 2018, closing a stake of 75 shares — an estimated $1K sold.

Delpha Capital Management first reported a position in ARRY in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 235 funds tracked by Wall St. Rank hold ARRY as of Q1 2018.

  • Delpha Capital Management reported no remaining Array Biopharma Inc position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 75 Array Biopharma Inc shares in Q1 2018, an estimated $1K.
  • Delpha Capital Management first reported a position in Array Biopharma Inc in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Array Biopharma Inc position peaked at $1K in Q4 2017.
  • 235 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.